ASH

Ashland Inc.
$66.38
-0.02 (-0.03%)
Mkt Cap 3.03B
Volume 672,630
52W Range 46.3-69.66
Sector Basic Materials
Beta 0.41
EPS (TTM) -15.34
P/E Ratio -2.61
Revenue (TTM) 1.81B
Rev Growth (5Y) -2.0%
EPS Growth (5Y) N/A
AlphaVal · Fair Value
What we estimate one share is worth
$61.71
Overvalued weak signal
7.3% above fair value
Modeled from cash flows & growth.
AlphaQuality · Grade
How strong & durable the business is
D-
Stable Earnings Power
29.1 / 100 composite
Steady, predictable earnings power — graded A–F vs. similar companies.

Company Description

Track Record

Showing latest 4 periods • Swipe for more
Metric 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014
Revenue 1.82B 2.11B 2.19B 2.39B 2.11B 2.02B 2.15B 2.59B 2.31B 3.02B 3.42B 6.12B
Net Income (845.00M) 169.00M 178.00M 927.00M 220.00M (508.00M) 505.00M 114.00M 1.00M (29.00M) 309.00M 233.00M
EPS -18.37 3.45 3.36 17.17 2.85 -8.33 8.15 1.84 0.02 -0.46 4.61 3.33
Free Cash Flow (4.00M) 274.00M 73.00M (326.00M) 455.00M 70.00M 87.00M 140.00M 166.00M 447.00M 69.00M 395.00M
FCF / Share -0.09 5.59 1.38 -6.04 5.83 1.15 1.38 2.26 2.68 7.10 1.03 5.64
Operating CF 94.00M 411.00M 243.00M (213.00M) 560.00M 203.00M 241.00M 297.00M 383.00M 678.00M 333.00M 643.00M
Total Assets 4.61B 5.64B 5.94B 6.21B 6.61B 6.88B 7.25B 8.25B 8.62B 10.00B 10.05B 10.95B
Total Debt 1.57B 1.47B 1.46B 1.38B 2.10B 1.99B 1.67B 2.53B 2.82B 2.50B 3.73B 3.25B
Cash & Equiv 215.00M 300.00M 417.00M 646.00M 210.00M 454.00M 232.00M 294.00M 566.00M 1.02B 1.26B 1.39B
Book Value 1.90B 2.87B 3.10B 3.22B 2.75B 3.04B 3.57B 3.41B 3.41B 3.35B 3.04B 3.58B
Return on Equity -0.44 0.06 0.06 0.29 0.08 -0.17 0.14 0.03 0.00 -0.01 0.10 0.07
ASH News
Ashland (ASH) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Jul 21, 2026 07:00 AM · zacks.com
Ashland sets date for third-quarter fiscal 2026 earnings release and conference call webcast
Jul 14, 2026 01:01 PM · globenewswire.com
Ashland sets date for third-quarter fiscal 2026 earnings release and conference call webcast
Jul 14, 2026 01:01 PM · globenewswire.com
Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with chronic lymphocytic leukemia (CLL) across all lines of therapy
Jun 26, 2026 04:00 AM · gurufocus.com
Ashland responds to investor presentation by Ancora Alternatives LLC
Jun 10, 2026 02:07 PM · globenewswire.com
Ashland responds to investor presentation by Ancora Alternatives LLC
Jun 10, 2026 02:07 PM · globenewswire.com
New Strong Sell Stocks for June 10th
Jun 10, 2026 01:21 AM · zacks.com
Ancora Releases Presentation Highlighting the Opportunity for a Value-Maximizing, Competitive Sale Process at Ashland Inc.
Jun 09, 2026 12:05 PM · businesswire.com
New Strong Sell Stocks for June 8th
Jun 08, 2026 04:05 AM · zacks.com
Dividend Champion, Contender, And Challenger Highlights: Week Of June 7
Jun 05, 2026 02:19 PM · seekingalpha.com